Contact
Please use this form to send email to PR contact of this press release:
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
TO:
Please use this form to send email to PR contact of this press release:
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
TO: